Paromomycin sulfate

Paromomycin
Systematic (IUPAC) name
(2R,3S,4R,5R,6S)-5-amino-6-[(1R,2S,3S,4R,6S)-
4,6-diamino-2-[(2S,3R,4R,5R)-4-[(2R,3R,4R,5R,6S)-
3-amino-6-(aminomethyl)-4,5-dihydroxy-oxan-2-yl]
oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-
3-hydroxy-cyclohexyl]oxy-2-(hydroxymethyl)oxane-3,4-diol
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a601098
Pregnancy cat. B(US)
Legal status Rx only U.S.
Routes Oral, intramuscular
Pharmacokinetic data
Bioavailability None
Metabolism None
Half-life  ?
Excretion Fecal
Identifiers
CAS number 1263-89-4 YesY
ATC code A07AA06
PubChem CID 441375
DrugBank DB01421
ChemSpider 390117 YesY
ChEMBL CHEMBL370143 N
Chemical data
Formula C23H47N5O18S 
Mol. mass 615.629 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  sulfate (verify)

Paromomycin (brand name Humatin) is an aminoglycoside antibiotic, first isolated from Streptomyces krestomuceticus in the 1950s.[1] It is also called monomycin and aminosidine[2];

Contents

Uses

It is an antibiotic designed to fight intestinal infections such as cryptosporidiosis,[3] amoebiasis,[4] and leishmaniasis.[5]

The route of administration is intramuscular injection and capsule.

Mechanism

Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA.[6]

History and availability

Paromomycin was demonstrated to be effective against cutaneous leishmaniasis in clinical studies in the USSR in the 1960s, and in trials with visceral leishmaniasis in the early 1990s.[2]

It was developed as a therapeutic against visceral leishmaniasis by the Institute for OneWorld Health. Paromomycin was granted orphan drug status in 2005[7] and was approved by the Drug Controller General of India in September 2006 for treatment of visceral leishmaniasis.[8]

As of February 5th, 2008, King Pharmaceuticals is discontinuing the sale of Humatin. Paromomycin continues to be available in the United States from another manufacturer.[9]

References

  1. ^ Davidson R.N., den Boer M., Ritmeijer K. (2008). "Paromomycin". Transactions of the Royal Society of Tropical Medicine and Hygiene 103 (7): 653–60. doi:10.1016/j.trstmh.2008.09.008. PMID 18947845. 
  2. ^ a b Neal R.A. et al. (1994). "Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis". Transactions of the Royal Society of Tropical Medicine and Hygiene 88 (2): 223–5. doi:10.1016/0035-9203(94)90307-7. PMID 8036682. 
  3. ^ Sweetman S.C. (Editor). (2002). Martindale: the complete drug reference. 33rd ed. London: Pharmaceutical Press
  4. ^ "paromomycin" at Dorland's Medical Dictionary
  5. ^ Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK (June 2007). "Injectable paromomycin for visceral leishmaniasis in India". N. Engl. J. Med. 356 (25): 2571–81. doi:10.1056/NEJMoa066536. PMID 17582067. http://content.nejm.org/cgi/pmidlookup?view=short&pmid=17582067&promo=ONFLNS19. 
  6. ^ Vicens, Quentin; Eric Westhof (August 2001). "Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site". Structure 9 (8): 647–658. doi:10.1016/S0969-2126(01)00629-3. PMID 11587639. http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VSR-43VBX2W-C&_user=10&_coverDate=08%2F31%2F2001&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=1b1e19d11ca34e14eca1603c2be009d5. Retrieved 2007-02-10. 
  7. ^ "Institute for OneWorld Health Drug Receives “Orphan” Designation From U.S. and European Regulatory Agencies" (Press release). Institute for OneWorld Health. 23 May 2005. http://www.oneworldhealth.org/media/details.php?prID=115. Retrieved 2007-02-10. 
  8. ^ "New cure for deadly visceral leishmaniasis (kala-azar) approved by government of India" (Press release). Institute for OneWorld Health. 8 September 2006. http://www.oneworldhealth.org/media/details.php?prID=154. Retrieved 2007-02-10. 
  9. ^ Food and Drug Administration (2010). "Drugs to be Discontinued". http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050794.htm. 

Wikimedia Foundation. 2010.

Look at other dictionaries:

  • paromomycin sulfate — A broad spectrum antibiotic produced by Streptomyces rimosus forma paromomycinus; used in the treatment of bacterial enteritis and amebiasis, and for preoperative suppression of intestinal bacteria. * * * [USP] the sulfate salt of paromomycin,… …   Medical dictionary

  • Paromomycin — Strukturformel Allgemeines Freiname Paromomycin Andere …   Deutsch Wikipedia

  • paromomycin — par·o·mo·my·cin .par ə mō mīs ən n a broad spectrum aminoglycoside antibiotic that is obtained from a bacterium of the genus Streptomyces (S. rimosus paromomycinus) and is usu. used in the form of its sulfate C23H45N5O14·H2SO4 to treat intestinal …   Medical dictionary

  • paromomycin — ˌparəmōˈmīsən noun ( s) Etymology: probably from Greek paromoios closely resembling (from par para + homoios like, similar) + English mycin more at home : a broad spectrum antibiotic C23H45N5O14 that is obtained from a bacterium of the genus… …   Useful english dictionary

  • aminosidine sulfate — ami·no·si·dine sul·fate (ə me″no siґdin) paromomycin sulfate …   Medical dictionary

  • crestomycin sulfate — cres·to·my·cin sul·fate (kres to miґsin) paromomycin sulfate …   Medical dictionary

  • Antiprotozoal agent — Antiprotozoal agents (ATC code: ATC P01) is a class of pharmaceuticals used in treatment of protozoan infection.Examples* Eflornithine * Furazolidone * Melarsoprol * Metronidazole * Ornidazole * Paromomycin sulfate * Pentamidine * Pyrimethamine * …   Wikipedia

  • Humatin — Hu·ma·tin (huґmə tin) trademark for preparations of paromomycin sulfate …   Medical dictionary

  • Colistin — Systematic (IUPAC) name N (4 amino 1 (1 (4 amino 1 oxo 1 (3,12,23 tris(2 aminoethyl) 20 (1 hydroxyethyl) 6,9 diisobutyl 2,5,8,11,14,19,22 heptaoxo 1,4,7,10,13,18 hexaazacyclotricosan 15 ylamino)butan 2 ylamino) 3 hydroxybutan 2 ylamino) 1… …   Wikipedia

  • Cryptosporidiosis — Not to be confused with Cryptococcus. Cryptosporidium Cryptosporidium muris oocysts found in human feces. Scientific classification …   Wikipedia


Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.